Matches in SemOpenAlex for { <https://semopenalex.org/work/W2465332775> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2465332775 endingPage "3" @default.
- W2465332775 startingPage "601" @default.
- W2465332775 abstract "The effect of interferons in the correction of thrombocytosis in chronic myeloproliferative syndromes is well known. In this study the efficacy of alpha-2b interferon in a regimen of induction followed by a phase of sequential maintenance to progressively decreasing doses was evaluated with the aim of knowing the minimum doses necessary to maintain response.The response to treatment with alpha-2b interferon was prospectively studied in a group of 37 patients with chronic myeloproliferative syndromes with associated thrombocytosis (excluding chronic myeloid leukemia). Likewise, the toxicity of the treatment was analyzed.Sixty-seven percent of the patients responded (platelets lower than 600 x 10(9)/1) to the daily administration of 3 or 5 MU of interferon. Forty percent of the patients who responded to the daily schedule of administration maintained the response upon receiving 3 doses weekly for 4 months. Half of the 8 patients who received 2 weekly doses of interferon for 4 months continued maintaining the responses. Only two of the 4 patients who received one sole weekly dose during the following 4 months maintained the response. Only one of the 37 patients who initiated treatment underwent progression of the symptoms present at the beginning of the study. Toxicity was high and was the cause of 12 discontinuations of treatment (32% of the patients) during the daily treatment phase (9 patients) or during maintenance of 3 weekly doses (3 patients). No toxicity was observed in the schedule of one or two weekly doses.Alpha-2b interferon is effective in the treatment of thrombocytosis of the chronic myeloproliferative syndromes (excluding chronic myeloid leukemia) when administered daily and is ever less so when the doses are spaced at 3, 2 or 1 week. The toxicity of interferon treatment is high when administered at affective doses." @default.
- W2465332775 created "2016-07-22" @default.
- W2465332775 creator A5000616827 @default.
- W2465332775 creator A5007898968 @default.
- W2465332775 creator A5020155090 @default.
- W2465332775 creator A5072725040 @default.
- W2465332775 creator A5080659205 @default.
- W2465332775 creator A5090853519 @default.
- W2465332775 date "1993-11-13" @default.
- W2465332775 modified "2023-09-23" @default.
- W2465332775 title "[Alfa-2b interferon in the treatment of thrombocytosis associated to chronic non leukemic myeloproliferative syndromes]." @default.
- W2465332775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8271861" @default.
- W2465332775 hasPublicationYear "1993" @default.
- W2465332775 type Work @default.
- W2465332775 sameAs 2465332775 @default.
- W2465332775 citedByCount "0" @default.
- W2465332775 crossrefType "journal-article" @default.
- W2465332775 hasAuthorship W2465332775A5000616827 @default.
- W2465332775 hasAuthorship W2465332775A5007898968 @default.
- W2465332775 hasAuthorship W2465332775A5020155090 @default.
- W2465332775 hasAuthorship W2465332775A5072725040 @default.
- W2465332775 hasAuthorship W2465332775A5080659205 @default.
- W2465332775 hasAuthorship W2465332775A5090853519 @default.
- W2465332775 hasConcept C126322002 @default.
- W2465332775 hasConcept C203014093 @default.
- W2465332775 hasConcept C2776178377 @default.
- W2465332775 hasConcept C2778837598 @default.
- W2465332775 hasConcept C2779788118 @default.
- W2465332775 hasConcept C2781413609 @default.
- W2465332775 hasConcept C2909179924 @default.
- W2465332775 hasConcept C29730261 @default.
- W2465332775 hasConcept C71924100 @default.
- W2465332775 hasConcept C89560881 @default.
- W2465332775 hasConcept C90924648 @default.
- W2465332775 hasConceptScore W2465332775C126322002 @default.
- W2465332775 hasConceptScore W2465332775C203014093 @default.
- W2465332775 hasConceptScore W2465332775C2776178377 @default.
- W2465332775 hasConceptScore W2465332775C2778837598 @default.
- W2465332775 hasConceptScore W2465332775C2779788118 @default.
- W2465332775 hasConceptScore W2465332775C2781413609 @default.
- W2465332775 hasConceptScore W2465332775C2909179924 @default.
- W2465332775 hasConceptScore W2465332775C29730261 @default.
- W2465332775 hasConceptScore W2465332775C71924100 @default.
- W2465332775 hasConceptScore W2465332775C89560881 @default.
- W2465332775 hasConceptScore W2465332775C90924648 @default.
- W2465332775 hasIssue "16" @default.
- W2465332775 hasLocation W24653327751 @default.
- W2465332775 hasOpenAccess W2465332775 @default.
- W2465332775 hasPrimaryLocation W24653327751 @default.
- W2465332775 hasRelatedWork W1550484024 @default.
- W2465332775 hasRelatedWork W1963742491 @default.
- W2465332775 hasRelatedWork W1974298468 @default.
- W2465332775 hasRelatedWork W1978860220 @default.
- W2465332775 hasRelatedWork W2068182812 @default.
- W2465332775 hasRelatedWork W2083180779 @default.
- W2465332775 hasRelatedWork W2123424163 @default.
- W2465332775 hasRelatedWork W2131611074 @default.
- W2465332775 hasRelatedWork W2395985200 @default.
- W2465332775 hasRelatedWork W2416381554 @default.
- W2465332775 hasVolume "101" @default.
- W2465332775 isParatext "false" @default.
- W2465332775 isRetracted "false" @default.
- W2465332775 magId "2465332775" @default.
- W2465332775 workType "article" @default.